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The main goals for urologists during the coronavirus disease 2019 (COVID-19) pandemic are to prevent their patients from getting COVID-19, protect themselves as health care professionals, and deliver optimal urology care [@bib0005]. While prioritisation strategies are being proposed [@bib0010], [@bib0015], further measures are warranted for multifaceted action plans towards optimal perpetuation of urology care during the pandemic [@bib0020].

Urological telemedicine can lead to (1) fewer patient contacts, (2) lower infection rates among the staff, and (3) continuation of urological care by quarantined urologists [@bib0025]. However, the proportion of patients eligible for telemedicine, their wish to use telemedicine, and their demographic risk profile for acquiring a severe pandemic infection are unknown.

In this context, we tested the potential of telemedicine in urology. We evaluated patients' eligibility for telemedicine according to the physician and examined the patients' perspective by evaluating their willingness for telemedicine. Furthermore, we assessed the risk profile of urological patients for a poor outcome of COVID-19.

We analysed 399 consecutive outpatients with scheduled appointments at our tertiary centre between October 2019 and February 2020. The institutional review board approved the study. All participants gave oral informed consent.

Prospective structured phone interviews were conducted between 18 and 24 March 2020. Information about age, reason for consultation, and medical history were collected. Information about 10 risk factors for a poor outcome of COVID-19 according to the Robert-Koch Institute (RKI) for disease surveillance and prevention was gathered. The patients' perspective was evaluated by asking the following question: "If your appointment was tomorrow during COVID-19 pandemic, would you prefer in-house appointments or telemedicine contact?"

Telemedicine was defined as videoconference. Eligibility for telemedicine was evaluated by four experienced physicians according to the patients' files at the time of consultation. Patients were classified as telemedicine eligible if their primary reason for consultation could be solved completely by telemedicine. On the contrary, if physical examination, current laboratory values, ultrasound, or other procedures were needed, patients were considered telemedicine ineligible. Statistics were performed using RStudio v0.98.953 (R Project for Statistical Computing, [www.R-project.org](http://www.R-project.org){#intr0005}).

The CONSORT diagram depicts the study design (Supplementary Fig. S1). The reason for consultation was mostly an oncological disease (243/399 patients, 60.9%). Most patients were older than 50 yr (346, 86.7%). Self-reported comorbidities consisted of cardiovascular disease (42.4%), diabetes (13.8%), pulmonary disease (16%), liver dysfunction (12%), renal dysfunction (34.1%), oncological disease (60.9%), and hypertension (56.1%). Immunosuppression was reported by 7.5% and a positive current smoking status in 11.6% (Supplementary Table S1).

A total of 338 patients (84.7%) wished for a telemedical consultation in case of pandemic. The reason for refusal of telemedical contact was mostly technical limitations (17.3%); 2.5% prefer personal contact with their physician.

A total of 252 patients (63.2%) were eligible for telemedicine according to the physician. Patients eligible for telemedicine were younger (69 vs 73 yr; *p* = 0.02) but had a higher number of risk factors for a severe course of COVID-19 (4 vs 3 \[interquartile range 2--4 vs 2--5\]; *p* ≤ 0.001). Eligibility for telemedicine was more prevalent in oncological patients than in nononcological patients (181 \[74.4%\] vs 71 \[45.5%\]; *p* \< 0.001; Supplementary Fig. S1).

Patients with renal cancer had the highest number of risk factors (median 5 [@bib0020], [@bib0025], [@bib0030], followed by patients with urothelial cancer (4 [@bib0020], [@bib0015], [@bib0020], [@bib0025]), prostate cancer (3 \[3--4.8\]) and nononcological disease (2 [@bib0010], [@bib0015], [@bib0020], [@bib0025]; [Fig. 1](#fig0005){ref-type="fig"} ).Fig. 1Patients numbers stratified according to diagnosis, number of risk factors, and eligibility for telemedicine. The number of risk factors was calculated as a sum of age ≥50 yr, circulatory disease, diabetes, respiratory disease, liver disease, renal disease, history of oncological disease, immunosuppression at the time of the interview, nicotine abuse (actual abuse), and hypertension. Patients were classified as telemedicine eligible if the primary reason for their consultation can be solved completely by telemedicine. By contrast, if in-person/on-site services such as physical examination, current laboratory values, ultrasound, or other procedures were needed, patients were classified as telemedicine ineligible. COVID-19 = coronavirus disease 2019.Fig. 1

In total, 216 (54.1%) patients were eligible for telemedicine and wished for a telemedical consultation. Characteristics of patients eligible for telemedicine and with a wish for a telemedical consultation versus those who do not wish for a telemedical consultation were comparable, except that the latter were significantly older (76 vs 68 yr, *p* \< 0.001; [Table 1](#tbl0005){ref-type="table"} ).Table 1Characteristics of patients eligible for telemedicine (*n* = 252) stratified according to their wish for telemedical consultation (positive vs negative).Table 1Patient perspective for telemedical consultationOverallPositiveNegative*p* Value*n* (%)252 (100)216 (85.7)36 (14.3)Age (yr), median (IQR)69 (60--76)68 (58--75)76 (70--79.2)\<0.001Patients' reason for denial of telemedicine, *n* (%)\<0.001NA201 (100)199 (99)2 (1)Other3 (100)1 (33.3)2 (66.7)Personal contact6 (100)0 (0)6 (100)Technical limitation42 (100)16 (38.1)26 (61.9)Reason for consultation, *n* (%)0.9Oncological181 (100)156 (86.2)25 (13.8)Nononcological71 (100)60 (84.5)11 (15.5)0.04Andrology14 (100)12 (85.7)2 (14.3)BPS10 (100)8 (80)2 (20)Testicular cancer2 (100)1 (50)1 (50)Incontinence/bladder dysfunction13 (100)8 (61.5)5 (38.5)Renal cancer40 (100)37 (92.5)3 (7.5)Other14 (100)13 (92.9)1 (7.1)Reconstructive urology8 (100)7 (87.5)1 (12.5)Penile cancer3 (100)2 (66.7)1 (33.3)Prostate cancer105 (100)94 (89.5)11 (10.5)Urothelial cancer31 (100)22 (71)9 (29)Urolithiasis5 (100)5 (100)0 (0)Urinary tract infection7 (100)7 (100)0 (0)No. of risk factors for severe COVID-19 infection, median (IQR)4 (2--5)4 (2--5)3.5 (3--5)0.9No. of risk factors for patients, *n* (%)0.9≤3120 (100)102 (85)18 (15)\>3132 (100)114 (86.4)18 (13.6)[^1][^2]

The RKI recently stated the risk factors for a severe outcome of COVID-19 [@bib0030]. These high-risk patients should protect themselves by avoiding social contact, particularly high-risk environments such as medical institutions. On the contrary, perpetuation of conditions requiring urgent treatment, such as cancer, is of utmost importance. Telemedical consultation could help solve the discrepancy between staying at home and getting professional medical advice.

Our findings show that a large proportion (54.1%) of our patients are eligible and willing to keep a telemedical appointment if they were scheduled during the COVID-19 pandemic. In addition, we found a positive association between a higher risk profile (odds ratio 1.71) and eligibility for telemedicine. On the contrary, no association was found between the number of risk factors and patients' wish for a telemedical consultation (*p* = 0.1). It might be possible that these patients do not reflect their own risk status or these older patients are not able to provide the technical requirements.

To the best of our knowledge, no data about COVID-19 risk factor distribution and urological diagnoses exist. Our findings show that patients with urological malignancies have a higher number of risk factors for a severe COVID-19 course than patients with nononcological disease (2 vs 4, *p* \< 0.001; data not shown). Oncological patients are older than nononcological patients (71 vs 65 yr, *p* \< 0.001; data not shown), and immunosuppression is more commonly used in cancer patients (3.2% vs 10.3%, *p* = 0.02; data not shown). Larson et al [@bib0035] showed that telemedical intervention in cancer patients is comparable with face-to-face interaction regarding quality of life. No data exist about oncological outcome in patients who received telemedical advice.

Our study is not without limitations. First, risk factors for a severe outcome of COVID-19 are not validated. Most risk factor analyses for an unfavourable outcome of COVID-19 are conducted in in-patient populations [@bib0040], [@bib0045]. A large Chinese study found in 1590 nationwide hospitalised cases that patients with diabetes, chronic obstructive pulmonary disease, hypertension, or malignancy are at higher risk for death, intensive care unit treatment, or receiving invasive ventilation [@bib0050]. Our risk factors are in line with these results.

Taken together, our study adds some important information about patients' perspective on telemedical consultation during COVID-19 pandemic. We found that overall 54.1% of our patients were both eligible and willing to be scheduled for telemedical appointments. In addition, we evaluated the number of risk factors for an unfavourable outcome of COVID-19 and urological condition, and found that patients with more risk factors and urological malignancies are significantly more often eligible for telemedicine.
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The following are Supplementary data to this article:Fig. S1Patient percentages stratified according to diagnosis and eligibility for telemedicine. Patients were classified as telemedicine eligible if their primary reason for consultation could be solved completely by telemedicine. By contrast, if in-person/on-site services such as physical examination, current laboratory values, ultrasound, or other procedures were needed, patients were classified as telemedicine ineligible.

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.eururo.2020.04.055>.

[^1]: BPS = bladder pain syndrome; COVID-19 = coronavirus disease 2019; IQR = interquartile range; NA = not available.

[^2]: Patients were classified as telemedicine eligible if their primary reason for consultation could be solved completely by telemedicine. By contrast, if in-person/on-site services such as physical examination, current laboratory values, ultrasound, or others were needed, patients were classified as telemedicine ineligible.
